source
- Altimmune's pemvidutide cuts heavy drinking days in Phase 2 trialAltimmune reported that its experimental GLP-1/GIP injection pemvidutide achieved its primary and key secondary goals in a Phase 2 study of alcohol use disorder. The double-blind trial enrolled 10…
- Oak Hill Bio to go public via SPAC merger, securing $175 million for Angelman syndrome programOak Hill Bio announced it will become a publicly traded company through a merger with the special purpose acquisition company Research Alliance Corporation III. The transaction will provide $75 mi…